figshare
Browse
1/1
5 files

Quantitative evaluation of the relative apparent diffusion coefficient values on multiparametric magnetic resonance imaging to predict higher Gleason score prostate cancer

dataset
posted on 2018-11-16, 12:28 authored by Seiji Kato, Shuichi Kamijima, Tsutomu Inaoka, Naoto Kamiya, Daisuke Sasai, Hitoshi Terada, Nobuyuki Hiruta, Hiroyoshi Suzuki

Introduction: Apparent diffusion coefficient (ADC) values on multiparametric magnetic resonance imaging (mpMRI) have been reported to correlate with high-Gleason score (GS) prostate cancer. However, the relative ADC values between tumor lesions and normal tissue have been suggested as more suitable than the absolute ADC values for evaluation of diffusion abnormalities, because absolute ADC values are susceptible to differences in scanners or scanner settings. The present study evaluated the usefulness of the relative assessment of ADC values between tumor lesions and normal tissue on preoperative mpMRI for the prediction of high-risk prostate cancer on radical prostatectomy specimens.

Materials and Methods: A retrospective analysis of 48 men who underwent radical prostatectomy between January 2013 and December 2014 was conducted. MpMRI was performed with a 3.0-T scanner using b-values of 0 and 1500 s/mm2. ADC values of the tumor (ADCTUMOR) and normal prostate and the relative ADC tumor/normal ratio (ADCTNR) were evaluated by two radiologists.

Results: The inter-rater reliability between two radiologists for ADCTUMOR measurement was high, with Pearson’s r = 0.982. There was no difference in ADCTUMOR between GS ≤7 and GS ≥8. In contrast, ADCTNR was significantly lower in GS ≥8 than in GS ≤7. ROC curves of ADCTNR to predict higher GS (≥8) showed better classification performance (AUC = 0.8243, p = .0012 by radiologist A and AUC = 0.7961, p = .0031 by radiologist B) than of ADCTUMOR.

Conclusions: The relative assessment of ADC values between tumor lesions and normal tissue could improve the detection rate of high-risk prostate cancers.

Funding

This work was supported by JSPS KAKENHI [Grant Number 15K06882] and [Grant Number 16K11030]. Hiroyoshi Suzuki received research grants from Astellas Pharma Inc., Takeda Pharmaceutical Co., Ltd., Novartis, Pfizer Inc., Daiichi Sankyo Co., Ltd., Taiho Pharmaceutical Co., Ltd., Kissei Pharmaceutical Co., Ltd., and Nippon Kayaku Co., Ltd. Hiroyoshi Suzuki received lecture fees from AstraZeneca, Astellas Pharma Inc., Takeda Pharmaceutical Co., Ltd., Sanofi S.A., Daiichi Sankyo Co., Ltd., Bayer AG, and Janssen Pharmaceuticals, Inc.

History

Usage metrics

    SCANDINAVIAN JOURNAL OF UROLOGY

    Licence

    Exports

    RefWorks
    BibTeX
    Ref. manager
    Endnote
    DataCite
    NLM
    DC